Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn (TTN)

• Status: Completed
• Trial end date: 2015-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Inhaled Beta-2 Agonist Versus Epinephrine For Treatment of Transient Tachypnea of Newborn:

Randomized controlled trial to assess:

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ahmed Noaman
• Treatments: Albuterol; Epinephrine

Criteria

Inclusion Criteria:

• babies with 35 weeks of gestation or more in the first 6 hours of life diagnosed with TTN according to the criteria of which are:

• Tachypnea (respiratory rate exceeding 60 breaths/ min) within 6 hours after birth

• Persistence of tachypnea for at least 12 hours

• Mild cyanosis, nasal flaring, or retractions.

• Chest radiograph indicating at least one of the following:

• Prominent central vascular markings

• Widened interlobar fissures

• Symmetrical perihilar congestion

• Hyperaeration is evidenced by flattening and depression of the diaphragmatic domes.

Exclusion Criteria:

• Newborn infants with gestational age < 35 weeks

• Meconium aspiration

• Respiratory distress syndrome

• Pneumonia

• Congenital heart diseases including persistent pulmonary hypertension of the neworn (PPHN)

• Sepsis or suspected sepsis

• Polycythemia

• Newborn infants with congenital malformations and chromosomal anomalies

• Newborn infants with ventilatory support.

• Newborn infants with arrhythmia